News & Updates

Temozolomide beyond 6 months tied to better survival in glioblastoma

28 Mar 2023

More than 6 cycles of extended adjuvant temozolomide (TMZ) therapy may result in better overall (OS) and progression-free survival (PFS) in patients with glioblastoma multiform, suggests a study.

Temozolomide beyond 6 months tied to better survival in glioblastoma

28 Mar 2023

CGM improves glycaemic, neonatal outcomes in pregnant women with T1D

28 Mar 2023

Combining continuous glucose monitoring (CGM) with continuous subcutaneous insulin infusion (CSII) therapy helps keep blood glucose levels low throughout pregnancy and lower the rate of large for gestational age (LGA) delivery, according to a study.

CGM improves glycaemic, neonatal outcomes in pregnant women with T1D

28 Mar 2023

Biologics lower exacerbation rates in severe asthma, allergic rhinitis

28 Mar 2023 by

Treatment with either omalizumab (anti-immunoglobulin E [anti-IgE]) or nonomalizumab (non-anti-IgE) biologics reduced exacerbations in patients with severe asthma and allergic rhinitis, with the benefits being more evident among those taking nonomalizumab agents, according to the CHRONICLE trial presented at AAAAI 2023.

Biologics lower exacerbation rates in severe asthma, allergic rhinitis

28 Mar 2023

Low, moderate glucocorticoid doses beneficial in severe fever with thrombocytopenia syndrome

27 Mar 2023

Treatment with low-to-moderate doses of glucocorticoids appears to help reduce case fatality rate among severe fever with thrombocytopenia syndrome (SFTS) patients with severe disease, as shown in a retrospective study.

Low, moderate glucocorticoid doses beneficial in severe fever with thrombocytopenia syndrome

27 Mar 2023

Chemotherapy plus ICI treatment ups VTE risk in cancer patients

27 Mar 2023

Combination treatment with immune checkpoint inhibitors (ICI) and chemotherapy is associated with a higher risk of venous thromboembolic events (VTE) in adult cancer patients, reveals a study. In addition, a similar VTE disease course is seen after ICI exposure, irrespective of other immune-related adverse events (irAEs).

Chemotherapy plus ICI treatment ups VTE risk in cancer patients

27 Mar 2023

Oral, on-the-skin immunotherapies show promise against peanut allergy in children

27 Mar 2023 by

Children who are allergic to peanuts may benefit from two immunotherapies, one oral and another epicutaneous or on-the-skin, which have demonstrated safety and efficacy in separate studies presented at the recent AAAAI 2023.

Oral, on-the-skin immunotherapies show promise against peanut allergy in children

27 Mar 2023

CAB+RPV LA vs B/FTC/TAF for HIV: Which is better?

27 Mar 2023 by

In virologically suppressed adults with HIV, the cabotegravir + rilpivirine long-acting (CAB+RPV LA) regimen was on par with bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF) in terms of virologic efficacy, but the former gained the upper hand over the latter in terms of patient satisfaction and preference, the SOLAR* study reports.

CAB+RPV LA vs B/FTC/TAF for HIV: Which is better?

27 Mar 2023

Ondansetron shows potential in irritable bowel syndrome with diarrhoea

27 Mar 2023

A study on titrated ondansetron for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) has fallen short of meeting the endpoint due to being underpowered. However, when data from this study and two others were pooled in a meta-analysis, ondansetron appears to yield significant improvements in the composite endpoint set by the Food and Drug Administration (FDA), namely stool consistency and urgency.

Ondansetron shows potential in irritable bowel syndrome with diarrhoea

27 Mar 2023

VANGUARD sets the stage for a novel biologic in HAE

27 Mar 2023 by

Monthly injections of the investigational biologic garadacimab substantially reduced the mean attack rate in patients with hereditary angioedema (HAE) in the phase III VANGUARD trial.

VANGUARD sets the stage for a novel biologic in HAE

27 Mar 2023

Dual inhibition of EGFR, VEGF improves progression-free survival in NSCLC

26 Mar 2023

Inhibiting the pathways of both epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) leads to significant improvements in progression-free survival (PFS) but more adverse events (AEs), results of a meta-analysis have shown.

Dual inhibition of EGFR, VEGF improves progression-free survival in NSCLC

26 Mar 2023

News & Updates

Filter by Specialty:

Specialty:

Temozolomide beyond 6 months tied to better survival in glioblastoma

Temozolomide beyond 6 months tied to better survival in glioblastoma

CGM improves glycaemic, neonatal outcomes in pregnant women with T1D

CGM improves glycaemic, neonatal outcomes in pregnant women with T1D

Biologics lower exacerbation rates in severe asthma, allergic rhinitis

Biologics lower exacerbation rates in severe asthma, allergic rhinitis

Low, moderate glucocorticoid doses beneficial in severe fever with thrombocytopenia syndrome

Low, moderate glucocorticoid doses beneficial in severe fever with thrombocytopenia syndrome

Chemotherapy plus ICI treatment ups VTE risk in cancer patients

Chemotherapy plus ICI treatment ups VTE risk in cancer patients

Oral, on-the-skin immunotherapies show promise against peanut allergy in children

Oral, on-the-skin immunotherapies show promise against peanut allergy in children

CAB+RPV LA vs B/FTC/TAF for HIV: Which is better?

CAB+RPV LA vs B/FTC/TAF for HIV: Which is better?

Ondansetron shows potential in irritable bowel syndrome with diarrhoea

Ondansetron shows potential in irritable bowel syndrome with diarrhoea

VANGUARD sets the stage for a novel biologic in HAE

VANGUARD sets the stage for a novel biologic in HAE

Dual inhibition of EGFR, VEGF improves progression-free survival in NSCLC

Dual inhibition of EGFR, VEGF improves progression-free survival in NSCLC